Infinity Pharmaceutical (INFI) PT Lifted to $19 at Nomura Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
JMP Securities Upgrades Infinity Pharmaceutical (INFI) to Market Outperform
September 4, 2014 6:46 AM EDTJMP Securities upgraded Infinity Pharmaceutical (NASDAQ: INFI) from Market Perform to Market Outperform with a price target of $24.00.
For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.
Shares of Infinity Pharmaceutical closed at $15.73 yesterday.
... MoreInfinity (INFI) News a Positive for TG Therapeutics (TGTX) - Roth Capital
September 3, 2014 1:37 PM EDTRoth Capital analyst Joseph Pantginis reiterated a Buy rating and $25 price target on TG Therapeutics (NASDAQ: TGTX) after Infinity (NASDAQ: INFI) announced a collaboration with AbbVie (NASDAQ: ABBV) for the development and... More
UPDATE: Wedbush Upgrades Infinity Pharma (INFI) to Neutral
September 3, 2014 12:42 PM EDT(Updated - September 3, 2014 12:56 PM EDT)
Wedbush upgraded Infinity Pharmaceutical (NASDAQ: INFI) from Underperform to Neutral and raised its price target to $15 (from $9) Analyst David M. Nierengarten said AbbVies licensing of IPI-145 reduces uncertainty.
"INFI will be... More
Infinity Pharmaceutical (INFI) Should Be Up at Least 50% Following AbbVie (ABBV) Agreement, Says RBC Capital
September 3, 2014 7:58 AM EDTRBC Capital maintained an Outperform rating on Infinity Pharmaceutical (NASDAQ: INFI) with a price target of $20. Earlier Infinity and AbbVie Inc. (NYSE: ABBV) announced a partnership to develop and commercialize duvelisib (IPI-145). In the view of analyst Michael J. Yee, terms of the deal are positive, and the stock could be up at least... More
Infinity Pharma (INFI), AbbVie (ABBV) Enter Commercialization Agreement Covering IPI-145
September 3, 2014 6:46 AM EDTInfinity Pharmaceuticals, Inc. (Nasdaq: INFI) and AbbVie Inc. (NYSE: ABBV) announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer. Duvelisib has shown clinical activity across a broad range of blood cancers, including indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). Infinity is conducting registration-focused trials evaluating the safety and efficacy of duvelisib, including... More
